Skip to main content

BioNTech SE (BNTX) Stock Forecast

Data as of Sep 18, 2026

Healthcare · Current price $97.34 (-1.36%)

Consensus Target
$129.57
Upside
+21.8%
Analysts
6
Rating
Buy(2.00)

Price Target Range

Low $96.00Consensus $129.57High $155.00
▲ Current $97.34

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

BNTX vs Sector & Market

MetricBNTXHealthcare AvgLarge Cap Avg
Analyst Rating2.002.262.42
Analyst Count6818
Target Upside+21.8%+16187.2%+19.5%
P/E Ratio-18.613.9238.51

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$485M$1.11B$2.77B2
2026-12-31$335M$768M$1.91B2
2027-03-31$72M$165M$412M2
2027-06-30$328M$751M$1.87B2
2027-09-30$125M$285M$711M2
2027-12-31$203M$464M$1.16B2

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$0.18$0.69$2.031
2026-12-31$-2.91$-0.99$-0.271
2027-03-31$-5.73$-1.95$-0.521
2027-06-30$-2.44$-0.83$-0.221
2027-09-30$-5.12$-1.74$-0.471
2027-12-31$0.20$0.76$2.231

Frequently Asked Questions

What is the analyst consensus for BNTX?

The consensus among 6 analysts covering BioNTech SE (BNTX) is Buy with an average price target of $129.57.

What is the highest price target for BNTX?

The highest analyst price target for BNTX is $155.00.

What is the lowest price target for BNTX?

The lowest analyst price target for BNTX is $96.00.

How many analysts cover BNTX?

6 analysts have issued ratings for BioNTech SE in the past 12 months.

Is BNTX a buy or sell right now?

Based on 6 analyst ratings, BNTX has a consensus rating of Buy (2.00/5) with a +21.8% upside to the consensus target of $129.57.

What are the earnings estimates for BNTX?

Analysts estimate BNTX will report EPS of $0.69 for the period ending 2026-09-30, with revenue estimated at $1.11B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.